Several PI3K inhibitors are approved by the FDA for different cancers: Alpelisib in HR+ and HER2/neu negative breast cancer [11], idelalisib for leukemia [33] and two types of lymphoma [34,35], duvelisib for chronic lymphocytic leukemia/small lymphocytic lymphoma [36]. This evidence concerns the gene PIK3CB and leukemia.